Caribou Biosciences shareholders reject officer exculpation charter amendment at annual meeting

• Caribou Biosciences held its annual shareholder meeting on June 17, 2026.
• Shareholders ratified Deloitte & Touche as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
• Shareholders rejected a charter amendment to add officer exculpation for certain fiduciary-duty breaches.
• Shareholders authorized an adjournment to seek additional support for that amendment, if needed; the meeting was not adjourned.
• Three Class II directors were selected to serve until the 2029 annual meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caribou Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001619856-26-000047), on June 18, 2026, and is solely responsible for the information contained therein.